Sorafenib plus tegafur–uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study)

por Azim, Hamdy A, Omar, Ashraf, Atef, Hesham, Zawahry, Heba, Shaker, Mohamed K, Abdelmaksoud, AH Kamel, EzzElarab, Mohamed, Abdel-Rahman, Omar, Ismail, Mohamed, Kassem, Loay, Waked, Imam
Publicado 2018